United States experience of insulin degludec alone or in combination for type 1 and type 2 diabetes

por Rendell, Marc
Publicado 2017

The journey from gene knockout to clinical medicine: telotristat and sotagliflozin

por Rendell, Marc S
Publicado 2019

Alogliptin: a new addition to the class of DPP-4 inhibitors

por Andukuri, Radha, Drincic, Andjela, Rendell, Marc
Publicado 2009

Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial

por Kothny, Wolfgang, Lukashevich, Valentina, Foley, James E., Rendell, Marc S., Schweizer, Anja
Publicado 2015

Adjust to Target in Type 2 Diabetes: Comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine

por Bergenstal, Richard M., Johnson, Mary, Powers, Margaret A., Wynne, Alan, Vlajnic, Aleksandra, Hollander, Priscilla, Rendell, Marc
Publicado 2008

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with typ...

por Nauck, Michael A., Stewart, Murray W., Perkins, Christopher, Jones-Leone, Angela, Yang, Fred, Perry, Caroline, Reinhardt, Rickey R., Rendell, Marc
Publicado 2015

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes

por Sands, Arthur T., Zambrowicz, Brian P., Rosenstock, Julio, Lapuerta, Pablo, Bode, Bruce W., Garg, Satish K., Buse, John B., Banks, Phillip, Heptulla, Rubina, Rendell, Marc, Cefalu, William T., Strumph, Paul
Publicado 2015